TY  - JOUR
T1  - COntaining antibiotic resistance while treating community-acquired pneumonia
AU  - Wise MP, Howe RA, Butler CC
Y1  - 2011/09/12
N1  - 10.1001/archinternmed.2011.382
JO  - Archives of Internal Medicine
SP  - 1510
EP  - 1510
VL  - 171
IS  - 16
N2  - 
Sordé and colleagues recently described the performance of a point-of-care pneumococcal urinary antigen test in an observational study of patients admitted to hospital with community-acquired pneumonia (CAP).1 The urinary antigen test was exclusively used to detect 43.8% of pneumococcal pneumonias or 15.8% of all patients with CAP, and this investigation therefore provides an important advance in the rapid diagnosis and treatment of hospitalized patients. The authors suggest that pathogen identification can improve patient treatment by allowing clinicians to safely narrow the spectrum of antibiotics, thereby reducing cost, adverse effects, and bacterial resistance. Resistance is increasingly important issue, given that there are few new antibiotics entering the clinical arena. Yu2 reinforces the idea in the accompanying Commentary that point-of-care can help by enabling the use of narrow-spectrum antibiotics at an earlier stage.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2011.382
UR  - http://dx.doi.org/10.1001/archinternmed.2011.382
ER  -